» Articles » PMID: 6155995

Common Human Melanoma-associated Antigen(s) Detected by Monoclonal Antibodies

Overview
Journal Cancer Res
Specialty Oncology
Date 1980 Jul 1
PMID 6155995
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Hybridoma cells have been derived from a fusion between mouse myeloma cells (P3-NSI/1Ag4) and spleen cells from a mouse immunized with membrane-enriched fractions from the human melanoma cell line Me-43. Of the 26 hybrids obtained, seven secreted antibodies which reacted with the melanoma cell line used for immunoassay. The specificity of the antibodies produced by the seven positive hybrids was further investigated on 16 melanoma cell lines, 15 other tumors, and 14 lymphoblastoid cell lines. The antibodies from four positive hybrids showed a broad reactivity, whereas those from three hybrids reacted exclusively with melanoma cells. The antibodies from two of these three hybrids, alpha-Mel/5 and alpha-Mel/14, seem to be directed against common melanoma antigen(s) since they reacted with all (with one exception) of the 16 melanoma cell lines tested only with five of the 16 melanoma lines. Reciprocal binding inhibition tests using [3H]leeucine-labeled antibodies showed that alpha-Mel/5 and alpha-Mel/14 antibodies were directed against different antigenic determinants.

Citing Articles

Toxin-based targeted therapy for malignant brain tumors.

Chandramohan V, Sampson J, Pastan I, Bigner D Clin Dev Immunol. 2012; 2012:480429.

PMID: 22400035 PMC: 3287048. DOI: 10.1155/2012/480429.


Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.

Cassard L, Cohen-Solal J, Galinha A, Sastre-Garau X, Mathiot C, Galon J J Clin Invest. 2002; 110(10):1549-57.

PMID: 12438452 PMC: 151807. DOI: 10.1172/JCI15454.


Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.

Coakham H, Kemshead J J Neurooncol. 1998; 38(2-3):225-32.

PMID: 9696376 DOI: 10.1023/a:1005996606073.


Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Bigner D, Brown M, Coleman R, Friedman A, Friedman H, McLendon R J Neurooncol. 1995; 24(1):109-22.

PMID: 8523067 DOI: 10.1007/BF01052668.


Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

Houghton A, Eisinger M, Albino A, Cairncross J, Old L J Exp Med. 1982; 156(6):1755-66.

PMID: 7175440 PMC: 2186870. DOI: 10.1084/jem.156.6.1755.